| 名稱 | β-thalassemia mutation Reference Standard Ⅲ |
| 型號 | CBPD0003 |
| 報價 |  |
| 特點 | β-thalassemia mutation Reference Standard Ⅲ |
產品搜索
相關文章
聯系我們
產品展示 / PRODUCTS
- 詳細內容
| Introduction | |
| Format | Genomic DNA |
| Description | β-thalassemia (β-mediterraneananemia) refers to the A group of hemoglobinopathies in which synthesis is partially or completely inhibited. |
| Technical Data | |
| Mutation 1 | Variation site: -87(C>G) |
| DNA Change: N/A | |
| Zygosity: Heterozygous | |
| Allelic Frequency: 50% | |
| Chr position(GRCh37): Chr11.5248388C>G | |
| Transcript: NM_000518.5 | |
| Mutation 2 | Variation site: IVS-I-110(G>A) |
| DNA Change: c.93-21G>A | |
| Zygosity: Heterozygous | |
| Allelic Frequency: 50% | |
| Chr position(GRCh37): Chr11.5248050C>T | |
| Transcript: NM_000518.5 | |
| Buffer | Tris-EDTA |
| Product Information | |
| Intended Use | Research Use Only |
| Unit Size | 1ug |
| Concentration | Download for COA |
| Purofication | Download for COA |
| DNA electrophoresis | Download for COA |
| Sanger sequencing |
Figure 1. -87(C>G) Heterozygous
Figure 2. IVS-I-110(G>A) Homozygous |
| Storage | 4℃ |
| Expiry | 36 months from the date of manufacture |
